New hope for advanced breast cancer: experimental drug ARV-471 shows promise in early trial

NCT ID NCT04072952

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 16 times

Summary

This study tested an experimental drug called ARV-471, alone or with another drug (palbociclib), in 217 people with a common type of advanced breast cancer (ER+/HER2-) that had stopped responding to standard treatments. The main goals were to check safety and see if the drug shrinks tumors or keeps them stable for at least 24 weeks. Participants had already received hormone therapy and chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Trial Site

    Palo Alto, California, 94304, United States

  • Clinical Trial Site

    San Francisco, California, 94158, United States

  • Clinical Trial Site

    Santa Monica, California, 90404, United States

  • Clinical Trial Site

    Norwalk, Connecticut, 06856, United States

  • Clinical Trial Site

    Fort Myers, Florida, 33901, United States

  • Clinical Trial Site

    Tampa, Florida, 33612, United States

  • Clinical Trial Site

    Chicago, Illinois, 60637, United States

  • Clinical Trial Site

    Boston, Massachusetts, 02114, United States

  • Clinical Trial Site

    Boston, Massachusetts, 02215, United States

  • Clinical Trial Site

    Ann Arbor, Michigan, 48109, United States

  • Clinical Trial Site

    St Louis, Missouri, 63110, United States

  • Clinical Trial Site

    East Brunswick, New Jersey, 08816, United States

  • Clinical Trial Site

    The Bronx, New York, 10461, United States

  • Clinical Trial Site

    Charlotte, North Carolina, 28204, United States

  • Clinical Trial Site

    Nashville, Tennessee, 37203, United States

  • Clinical Trial Site

    Seattle, Washington, 98109, United States

Conditions

Explore the condition pages connected to this study.